Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-05-24
2005-05-24
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S320100, C435S325000, C435S252330, C435S029000, C536S024500
Reexamination Certificate
active
06897024
ABSTRACT:
This invention describes the cloning and characterization of the promoter region for the PCA3dd3gene. This region regulates the PCA3dd3gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.
REFERENCES:
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 20020022248 (2002-02-01), Xu et al.
patent: 20020035244 (2002-03-01), Cohen et al.
patent: 0 160 228 (1985-11-01), None
patent: 0 520 794 (1992-12-01), None
patent: WO 9409820 (1994-05-01), None
patent: WO 9528498 (1995-10-01), None
patent: WO 9614875 (1996-05-01), None
patent: WO 9845420 (1998-10-01), None
patent: WO 0004149 (2000-01-01), None
patent: WO 0125272 (2001-04-01), None
patent: WO 0125273 (2001-04-01), None
patent: WO 0134802 (2001-05-01), None
patent: WO 0151633 (2001-07-01), None
patent: WO 0160860 (2001-08-01), None
patent: WO 0173032 (2001-10-01), None
patent: WO 0224718 (2002-03-01), None
patent: WO 0230268 (2002-04-01), None
Verhaegh et al. J. Biol. Chem., vol. 275, No. 48 (2000) pp. 37496-37503.*
Tamimi, Y., et al., DiagnoGene PCA3 reliable NASBA based reagents for detecting PCA3 rnRNA, a recently described prostate marker,Proc. Am. Assoc. Cancer Res. 39:234 Poster Abstract (1998).
Bussemakers, M.J. and Isaacs, W.B., “Identification of Genes Associated with Phosphate Cancer Development,”Urol. Res. 21:452, Abstract No. P42, Springer International (1993).
Bussemakers, M.J.G. and Isaacs, W.B., “Identification of Genes Associated with Cancer Development,”8th Annual Spring Meeting, Society for Basic Urologic Research, one page. Society for Basic Urologic Research (1994).
Bussemakers, M.J.G., et al., “Identification of DD3: A New Gene Overexpressed in Prostatic Tumors,”Urol. Res23:253, Abstract No. 0 36, Springer International (1995).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Fall Symposium, Society for Basic Urologlc Research, one page, Society for Basic Urologic Research (1995).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Breast and Prostate Cancer: Basic Mechanisms, Abstract No. 102, pp. 17 (1996).
Bussemakers, M.J.G., et al., “DD3: a new prostate specific marker, overexpressed in prostatic tumors,”Proc. Am. Assoc. Cancer Res. Ann. Meeting37:515, Abstract No. 3522, American Association for Cancer Research (1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,”Meeting for the Dutch Association for Tumor Cell Biology(1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate-Specific Marker, Strongly Overexpressed in Prostatic Tumors,”Urol. Res. 25:76, Abstract No. 02.2, Springer International (1997).
Bowie, J.U., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1311, American Association for the Advancement of Science (1990).
Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biol.111:2129-2138, The Rockefeller University Press (1990).
Gandini, O., “Is DD3 a New Prostate-specific Gene?,”Anticancer Res.23:305-308, J.G. Delinassios (Jan.-Feb. 2003).
Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell. Biol. 8:1247-1252, American Society for Microbiology (1988).
Co-Pending U.S. Appl. No. 09/675,650, Busse, et al., filed Sep. 29, 2000 (Not Published).
Co-Pending U.S. Appl. No. 60/445,436, filed Feb. 7, 2003 (Not Published).
Co-Pending U.S. Appl. No. 09/402,713, Bussemakers, M.J., filed Oct. 8, 1999 (Published).
Altschul, S.F. et al., “Gapped Blast and PSI-Blast: a new generation of protein database search programs,”Nucl. Acids. Res.25:3389-3402, Oxford University Press (1997).
Boulikas, T., “Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets,”Anticancer Res.17:1471-1505, International Institute of Anticancer Research (1997).
Brakebusch, C. et al., “Expression of the 90K Immunostimulator Gene Is Controlled by a Promoter with Unique Features,”J. Biol. Chem.272:3674-3682, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Bussemakers, M.J.G. et al., “DD3: A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer,”Cancer Res.59:5975-5979, The American Association for Cancer Research (1999).
Bussemakers, M.J.G., “Changes in Gene Expression and Targets for Therapy,”Eur. Urol.35:408-412, S. Karger AG (1999).
Cleutjens, K.B.J.M. et al., “An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter,”Mol. Endocrinol. 11:148-161, The Endocrine Society (1997).
Cleutjens, K.B.J.M. et al., “A 6-kb Promoter Fragment Mimics in Transgenic Mice the Prostate-Specific and Androgen-Regulated Expression of the Endogenous Prostate-Specific Antigen Gene in Humans,”Mol. Endocrinol. 11:1256-1265, The Endocrine Society (1997).
Gotoh, A. et al., “Development of Prostate-Specific Antigen Promoter-Based Gene Therapy For Androgen-Independent Human Prostate Cancer,”J. Urol.160:220-229, American Urological Association, Inc. (1998).
Hsing, A.W. et al., “International Trends and Patterns of Prostate Cancer Incidence and Mortality,”Int. J. Cancer(Pred. Oncol.) 85:60-67, Wiley-Liss, Inc. (Jan. 2000).
Landis, S.H. et al., “Cancer Statistics, 1999,”CA Cancer J. Clin.49:8-31, American Cancer Society (1999).
Martiniello-Wilks, R. et al., “In Vivo Gene Therapy for Prostate Cancer: Preclinical Evaluation of Two Different Enzyme-Directed Prodrug Therapy Systems Delivered by Identical Adenovirus Vectors,”Human Gene Therapy9:1617-1626, Mary Ann Liebert, Inc. (1998).
Millikan, R.E., “Chemotherapy of Advanced Prostatic Carcinoma,”Semin. Oncol.26:185-191, W.B. Sauders Company (1999).
Pang, S. et al., “ldentification of a Positive Regulatory Element Responsible for Tissue-specific Expression of Prostate-specific Antigen,”Cancer Res.57:495-499, The American Association for Cancer Research (1997).
Quandt, K. et al., “MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data,”Nucl. Acids. Res.23:4878-4884, Oxford University Press (1995).
Schalken, J., “Molecular Diagnostics and Therapy of Prostate Cancer: New Avenues,”Eur. Urol.34(supp1 3):3-6, S. Karger AG (1998).
Schuur, E.R. et al., “Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer,”J. Biol. Chem.271:7043-7051, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Taneja, S.S. et al., “Gene Therapy: Principles and Potential,” inCancer Surveys 23: Preventing Prostate Cancer: Screening versus Chemoprevention, Oliver, R.T.D. et al., eds., Cold Spring Harbor Laboratory Press, pp. 247-266 (1995).
Wei, C. et al., “Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy,”Proc. Natl. Acad. Sci. USA94:6369-6374, The National Academy of Scien
Bussemakers Marion J.
Schalken Jack A.
Verhaegh Gerald
Ketter James
Sterne Kessler Goldstein & Fox P.L.L.C.
Stichting Katholieke Universiteit more particularly The Universi
LandOfFree
Nucleic acid molecules comprising the promoter for PCA3, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid molecules comprising the promoter for PCA3, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid molecules comprising the promoter for PCA3, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3434645